Kiora Pharmaceuticals (KPRX) Non Operating Income (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Non Operating Income came in at $139338.0 in Q1 2026, down 46.49% YoY from $260380.0 in Q1 2025, and down 2.96% on a QoQ basis from $143595.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Non Operating Income (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Non Operating Income data on file, last reported at $139338.0 in Q1 2026.
- Quarterly Non Operating Income fell 46.49% year-over-year to $139338.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $592727.0 (down 47.4% YoY) and the FY2025 annual result came in at $713770.0, down 37.9% from the prior year.
- Non Operating Income declined to $139338.0 in Q1 2026, from $143595.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $342102.0 in Q2 2024 to a low of -$1.4 million in Q3 2022.
- A 5-year average of $49841.0 and a median of $139338.0 in 2026 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 546935.52% — and 2023, when it jumped 3544.87%.
- Tracing KPRX's Non Operating Income over 5 years: stood at $23542.0 in 2022, then surged by 48.05% to $34855.0 in 2023, then soared by 862.45% to $335461.0 in 2024, then plunged by 57.19% to $143595.0 in 2025, then decreased by 2.96% to $139338.0 in 2026.
- The last three Non Operating Income figures came in at $139338.0 (Q1 2026), $143595.0 (Q4 2025), and $178114.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 134,761.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146,232.00 |
| Mar 31, 2026 | 139,338.00 |
| Dec 31, 2025 | 143,595.00 |
| Sep 30, 2025 | 178,114.00 |
| Jun 30, 2025 | 131,680.00 |
| Mar 31, 2025 | 260,380.00 |
| Dec 31, 2024 | 335,461.00 |
| Sep 30, 2024 | 188,911.00 |
| Jun 30, 2024 | 342,102.00 |
| Mar 31, 2024 | 231,113.00 |
| Dec 31, 2023 | 34,855.00 |
| Sep 30, 2023 | 155,627.00 |
| Jun 30, 2023 | 45,087.00 |
| Mar 31, 2023 | 48,131.00 |
| Dec 31, 2022 | 23,542.00 |
| Sep 30, 2022 | -1.42 Mn |
| Jun 30, 2022 | 1,237.00 |
| Mar 31, 2022 | 4,428.00 |
| Dec 31, 2021 | -3,832.00 |
| Sep 30, 2021 | 259.00 |